Long-term results of postoperative and definitive (chemo)radiotherapy in sinonasal carcinoma. Adult Comorbidity Evaluation 27 score as a predictor of survival.
chemoradiotherapy
curative radiotherapy
prognostic factors
sinonasal carcinoma
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
07
2022
accepted:
29
03
2023
medline:
17
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
The objective was to evaluate the efficacy and toxicity of curative radiotherapy in patients with sinonasal carcinoma and to identify prognostic factors influencing treatment outcomes. The authors conducted a retrospective study of 61 consecutive patients treated with postoperative or definitive radiotherapy from 2002 to 2018 (median age 59 years, current/former smokers 71%, maxillary sinus 67%, nasal cavity 26%). The majority of patients were diagnosed with locally advanced disease (85% clinical stage ≥ III). Regional cervical metastases were initially diagnosed in 23% of patients. The most common histology was squamous cell carcinoma (61%). Radiation therapy was preceded by radical surgery in 64% of patients. 29 patients received chemotherapy (48%). The median follow-up was 53 months. The median total dose of radiotherapy achieved was 70 Gy. The 5- and 10-year locoregional control, distant control, overall survival, and disease-free survival were 74% and 64%, 90% and 90%, 51% and 35%, and 38% and 25%, respectively. Severe acute toxicity occurred in 36%, severe late toxicity in 23% of patients. Severe unilateral visual impairment occurred in 6 patients, temporal lobe necrosis in 1 patient, and osteoradionecrosis requiring surgery in 2 patients. The results of the study demonstrated the high effectiveness of curative treatment in patients with sinonasal carcinoma with long-term locoregional and distant control. The multivariate analysis indicated that N-staging, age, comorbidity score [as assessed by Adult Comorbidity Evaluation 27 (ACE-27)] and initial response to treatment were the strongest prognostic factors.
Sections du résumé
Background
UNASSIGNED
The objective was to evaluate the efficacy and toxicity of curative radiotherapy in patients with sinonasal carcinoma and to identify prognostic factors influencing treatment outcomes.
Materials and methods
UNASSIGNED
The authors conducted a retrospective study of 61 consecutive patients treated with postoperative or definitive radiotherapy from 2002 to 2018 (median age 59 years, current/former smokers 71%, maxillary sinus 67%, nasal cavity 26%). The majority of patients were diagnosed with locally advanced disease (85% clinical stage ≥ III). Regional cervical metastases were initially diagnosed in 23% of patients. The most common histology was squamous cell carcinoma (61%). Radiation therapy was preceded by radical surgery in 64% of patients. 29 patients received chemotherapy (48%).
Results
UNASSIGNED
The median follow-up was 53 months. The median total dose of radiotherapy achieved was 70 Gy. The 5- and 10-year locoregional control, distant control, overall survival, and disease-free survival were 74% and 64%, 90% and 90%, 51% and 35%, and 38% and 25%, respectively. Severe acute toxicity occurred in 36%, severe late toxicity in 23% of patients. Severe unilateral visual impairment occurred in 6 patients, temporal lobe necrosis in 1 patient, and osteoradionecrosis requiring surgery in 2 patients.
Conclusion
UNASSIGNED
The results of the study demonstrated the high effectiveness of curative treatment in patients with sinonasal carcinoma with long-term locoregional and distant control. The multivariate analysis indicated that N-staging, age, comorbidity score [as assessed by Adult Comorbidity Evaluation 27 (ACE-27)] and initial response to treatment were the strongest prognostic factors.
Identifiants
pubmed: 37456702
doi: 10.5603/RPOR.a2023.0017
pii: rpor-28-2-147
pmc: PMC10348334
doi:
Types de publication
Journal Article
Langues
eng
Pagination
147-158Informations de copyright
© 2023 Greater Poland Cancer Centre.
Déclaration de conflit d'intérêts
Conflicts of interest None declared.
Références
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):691-702
pubmed: 17161557
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):252-9
pubmed: 22027259
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1042-50
pubmed: 17570610
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):368-376
pubmed: 27084654
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):151-7
pubmed: 17189068
Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):283-9
pubmed: 9308929
Arch Otolaryngol Head Neck Surg. 2008 Oct;134(10):1045-9
pubmed: 18936348
Indian J Otolaryngol Head Neck Surg. 1999 Jan;51(1):15-20
pubmed: 23119476
Head Neck. 2004 Apr;26(4):322-30
pubmed: 15054735
Ann Oncol. 2013 Nov;24(11):2740-5
pubmed: 23946330
Radiother Oncol. 2006 Dec;81(3):243-9
pubmed: 17050017
Cancer. 2001 Dec 15;92(12):3012-29
pubmed: 11753979
JAMA. 2004 May 26;291(20):2441-7
pubmed: 15161894
Head Neck. 2004 May;26(5):435-41
pubmed: 15122660
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):27-35
pubmed: 10924968
Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1079-83
pubmed: 12220216
Head Neck. 2008 Jul;30(7):925-32
pubmed: 18302261
Oral Maxillofac Surg. 2009 Dec;13(4):191-9
pubmed: 19795137
Jpn J Clin Oncol. 2016 Jul;46(7):646-51
pubmed: 27162318
Laryngoscope. 1985 Mar;95(3):344-7
pubmed: 3974390
Radiother Oncol. 2000 Nov;57(2):167-73
pubmed: 11054520
Head Neck. 2002 Sep;24(9):821-9
pubmed: 12211046
Cancer. 1999 Nov 1;86(9):1700-11
pubmed: 10547542
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):141-7
pubmed: 17459609
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):424-32
pubmed: 18755554
Cancer. 2005 Jul 1;104(1):71-82
pubmed: 15915466
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):377-385
pubmed: 27084655
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):51-8
pubmed: 15093898
Radiother Oncol. 1991 Jul;21(3):193-200
pubmed: 1924855